You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)附屬兩藥擬中選集中採購 一藥獲頒藥品註冊證書
阿思達克 06-24 17:41
華潤醫藥(03320.HK)旗下子公司華潤三九(000999.SZ)公布,華潤三九全資子公司眾益製藥的藥品注射用頭孢唑林鈉(0.5g)、全資子公司九新藥業的藥品注射用頭孢他啶(1.0g)擬中選國家組織藥品集中採購和使用聯合採購辦公室組織的第五批國家藥品集中採購。另華潤三九控股子公司深圳華潤九創醫藥近日收到國家藥監局頒發複他舒的《藥品註冊證書》。

注射用頭孢唑林鈉適用於治療敏感細菌所致的感染,注射用頭孢他啶適用於治療敏感微生物引起的單一或多重感染。擬中選的兩款藥品於近日通過或視同通過仿製藥質量和療效一致性評價。截至目前,注射用頭孢唑林鈉未進行銷售,注射用頭孢他啶銷售收入佔公司總體營收比例極小。若後續簽訂採購合同並實施,公司子公司將進一步擴大上述產品的銷售,提升市場競爭力,有利於降低藥品集中採購等政策對公司抗感染業務的影響。

複他舒屬於2類新藥,該產品獲得藥品註冊證書有助於公司進一步豐富產品管線、優化產品結構,對公司創新轉型發展有積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account